Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Cardiology
•
Cardiovascular Imaging
How do you distinguish between senile/hypertensive sigmoid septal hypertrophy versus sigmoid septal hypertrophy seen in hypertrophic cardiomyopathy?
Related Questions
What is a reasonable imaging modality for older patients with pAfib already on systemic anticoagulation outpatient but presenting with suspected cardioembolic stroke and TTE without evidence of LV thrombus?
What is the role of MRI in assessing the risk of embolism in patients with persistent left ventricular thrombus following myocardial infarction?
What are some TTE findings that suggest worsening function of a bioprosthetic AVR that would require further surveillance or diagnostic imaging?
Should there be age cut-off considerations when ordering TTEs with bubble routinely as part of stroke work-up?
Do you prefer CTA or MRA for further imaging in patients with ascending aortic dilatation detected on TTE?
How soon would you repeat PET/CT in a patient with cardiac sarcoid after starting treatment with infliximab?
How would you further risk stratify patients with systemic vasculitides and chest pain with atypical features?
What are some practical ways to incorporate cardiac POCUS in the primary care setting?
Do you use DOAC in patients with mild or moderate rheumatic mitral stenosis?
Would it be reasonable to begin considering GLP1 RAs or finerenone for patients with heart failure with recovered LVEF in light of recent trials such as SELECT and FINEARTS-HF showing some success in HFpEF and HFmrEF populations?
